Zhitong Financial APP learned that$Pfizer Inc (PFE.US) $It was announced on Monday that it had agreed to the acquisitionGlobal Blood Therapy (GBT.US) $And plans to buy the maker of sickle cell disease (SCD) drugs for a total enterprise value of $5.4 billion.

Under the terms of the agreement, Pfizer Inc will buy the company that sells Oxbryta tablets, a sickle cell disease drug, for $68.50 a share in cash. The acquisition is likely to give Pfizer Inc a foothold in the treatment of sickle cell disease after the company's own drugs suffered a setback in the market.

Global Blood Therapy (GBT)'s development pipeline and Oxbryta are likely to generate the highest global sales of more than $3 billion, according to the two companies.

On Friday, the Wall Street Journal reported that the two companies were in advanced negotiations to reach a deal, sending GBT shares up more than 33% as of Friday's close.